As CML LSCs still share a differentiation ability with normal HSCs, CP-CML LSCs simultaneously differentiate into various morphologically mature but molecularly malignant BCR-ABL-expressing leukocytes. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.